In 2015, NICE said that BioMarin's Vimizim could be used to treat patients with the ultra-rare disease Morquio A syndrome, while real-world data was collected on its efficacy. Now – almost seven ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback